BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
Biocytogen’s RenLite® mice platform can produce fully human antibodies with diverse epitopes and high affinity. This platform is notable for its ability to generate antibodies in a common light chain format, offering a distinctive combination of design flexibility, simplified manufacturing processes, and optimal developability for bsADC development. Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases. ABL’s consistent success in advancing its pipeline strongly showcases its expertise and capabilities in regulatory, clinical development, and business development activities. BsADC drugs derived from our RenLite® mice platform have shown preferable potency in various tumor models, while also exhibiting good safety profiles. We believe our fully human bsADC platform technology, which features increased tumor selectivity, target synergized internalization, and convenient CMC development, will complement ABL's capabilities effectively. Together, we aim to expedite the development of innovative bsADC therapies.”
Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs. This collaboration is one of the stepping stones for getting down to developing bsADCs. We look forward to a productive collaboration, and firmly believe that this partnership will contribute towards creating a distinctive pipeline, ultimately leading to novel therapies that improve the quality of life for patients.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About ABL Bio
ABL Bio Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325027750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ardian Set to Mobilize Development Finance Institutions (DFIs) With European Investment Bank (EIB), Proparco and British International Investment (BII) for a €100m Commitment for Its Nature-Based Solutions Strategy12.11.2025 17:12:00 CET | Press release
Ardian’s Nature-Based Solutions strategy is dedicated to investing in projects in reforestation, wetlands and mangrove restoration intended to protect biodiversity. The strategy aims at providing carbon credit to corporates in their decarbonisation strategy. It will enable the sequestration of 85 million tons of carbon from the atmosphere over a 40 year’ period. European Investment Bank commits €50m and Proparco €20m and British International Investment intend to commit €10m, reflecting increasing DFIs appetite in the sector. Ardian, a world-leading private investment firm, today announces that it has secured commitment from several Development Finance Institutions (DFIs), the European Investment Bank (EIB) and Proparco. British International Investment (BII) have signaled their intention to provide commitment to the Nature Based Solutions fund. Total fund commitments will stand for a total of c. €100m by year end to Ardian’s Nature-Based Solutions (NBS) strategy. As anchor investors,
ViTAA Medical Secures FDA 510(k) Clearance for AiORTA™ Plan — Marking the First Step in Its Hyper-Precise Aortic Care Platform12.11.2025 16:00:00 CET | Press release
FDA clearance marks a pivotal milestone in ViTAA’s broader AiORTA™ suite, designed to support physicians across the full continuum of aortic care ViTAA Medical Solutions Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for AiORTA™ Plan, the company’s fully automated, hyper-precise aortic surgery planning solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112394413/en/ This clearance represents a key milestone in the evolution of ViTAA’s broader AiORTA™ platform, built to support physicians across the full continuum of aortic care. ViTAA’s additional innovations—AiORTA™ Maps and AiORTA™ Watch—are currently in multicenter clinical studies, progressing rapidly toward future clinical release. A Leap Forward in Aortic Surgery Planning Built to automate key preoperative measurements and streamline aortic case prep, AiORTA™ Plan generates a complete aortic plan in minutes.
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 202512.11.2025 15:30:00 CET | Press release
– Multiple presentations on vimseltinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT), including encore data from the Phase 3 MOTION study presented in an oral session – – Two posters on DCC-3009 in Gastrointestinal Stromal Tumor (GIST) – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that data from multiple pipeline programs, including long-term and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option, will be presented during the CTOS Annual Meeting 2025, taking place November 12-15 in Boca Raton, Florida. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112742665/en/ “We are excited about the breadth of data we’re presenting at CTOS this year, which underscore the strong progress we continue to sustain across our pipeline,” said Matthew L. Sherman, M.D
Deskpro Launches New Private Help Desk Solution with Private AI Support for Organizations with Strict Security, Compliance, and Data Sovereignty Requirements12.11.2025 15:13:00 CET | Press release
Deskpro Private Eliminates Impossible Choice Between AI Capabilities and Data Security for Organizations Including Financial Services, Healthcare, Aerospace and Defense, and Government Today, Deskpro, provider of the secure AI-powered help desk platform, announced the launch of Deskpro Private, making AI-powered help desk capabilities available to industries with stringent security and compliance requirements for the first time. The new platform delivers flexible private deployment, allowing companies to run their AI-powered help desk entirely within their AWS Virtual Private Cloud (VPC), on-premise enterprise data center, or sovereign cloud. Enterprises can connect to their AI of choice, including commercial, public, private, custom, and open source models, using existing organizational accounts and APIs. This means sensitive data never leaves the organization’s approved security perimeter. With Deskpro, organizations no longer need to sacrifice the measurable ROI from AI capabilities
New Study Reveals Tech Industry Leads AI Adoption in Support Operations at 92%; Regulated Industries Only at 58% Due to Compliance Constraints12.11.2025 15:06:00 CET | Press release
Research Finds Security and Compliance Requirements Are Reshaping Technology Adoption, with Healthcare, Finance, and Government Organizations Facing Deployment Constraints that Technology Companies Avoid Today, Deskpro, provider of the secure AI-powered help desk platform, released results from the State of AI in Support Operations: Balancing Innovation and Compliance report, which quantifies how security and compliance requirements are creating distinct market segments with vastly different AI adoption rates. According to the data, 92% of technology companies are adopting AI for support operations, while companies in regulated industries are significantly lagging behind with a 58% adoption rate. This 34-point gap reflects a significant disconnect: organizations are eager to adopt AI-powered support solutions, but face significant barriers related to data security, compliance and regulatory requirements, and deployment flexibility. While market demand for AI support capabilities exists
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom